Ligands acting on receptors are considered to induce a conformational change within the ligand-binding site by interacting with specific amino acids. In this study, tyrosine 102 (Y102) located in the GABA binding site of the ρ 1 subunit of the GABA C receptor was mutated to alanine (ρ 1Y102A ), serine (ρ 1Y102S ), and cysteine (ρ 1Y102C ) to assess the role of this amino acid in the action of 12 known and 2 novel antagonists. Of the mutated receptors, ρ 1Y102S was constitutively active, providing an opportunity to assess the activity of antagonists on ρ 1 receptors with a proportion of receptors existing in the open conformational state compared to those existing predominantly in the closed conformational state. It was found that the majority of antagonists studied were able to inhibit the constitutive activity displayed by ρ 1Y102S , thus displaying inverse agonist activity. The exception was (±)-4-aminocyclopent-1-enecarboxamide ((±)-4-ACPAM) (8) not exhibiting any inverse agonist activity, but acting explicitly on the closed conformational state of ρ 1 receptors (ρ 1 wild-type, ρ 1Y102C and ρ 1Y102A ). It was also found that the GABA antagonists were more potent at the closed compared to the open conformational states of ρ 1 receptors, suggesting that they may act by stabilizing closed conformational state and thus reducing activation by agonists. Furthermore, of the antagonists tested, Y102 was found to have the greatest influence on the antagonist activity of gabazine (SR-95531 (13)) and its analogue (SR-95813 (14)). This study contributes to our understanding of the mechanism of inverse agonism. This is important, as such agents are emerging as potential therapeutics.
γ-Aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the mammalian central nervous system (CNS), activating three receptors termed GABA A , GABA B , and GABA C . The GABA C receptor is found on the retina and at distinct anatomical areas within the CNS, including the superior colliculus, 1 cerebellum, 2 hippocampus, 3 and lateral amygdala, 4 and has been shown to play an important role in the onset of myopia, 5 the sleep-waking process, 6 memory enhancement, 7 and fear and anxiety disorders. 4 The design of potent and selective GABA C receptor antagonists, along with understanding how these agents modulate the receptor, will help characterize these receptors and establish whether GABA C receptors play a major role in various CNS disorders. 8, 9 GABA C receptors belong to the Cys-loop ligand-gated ion channel (LGIC) superfamily. 10 All members of this superfamily require five subunits to form functional receptors. In mammals, GABA C receptors are composed of three ρ subunits, ρ 1 −ρ 3 , which form homomeric receptors or pseudohomomeric receptors, composed of ρ 1 ρ 2 or ρ 2 ρ 3 subunit combina-tions. 11−13 The orthosteric binding site of the Cys-loop receptors is located at the interface of two subunits, formed by residues drawn from five discontinuous stretches of amino acids from the N-terminal domain of each subunit. These stretches of residues are referred to as loops A−E. Loops A−C form the principle side of the binding site and loops D and E form the complementary side. 14 GABA C receptors potentially have five orthosteric or GABA binding sites; GABA binding to these sites induce conformational changes within the receptor that subsequently lead to the opening of the pore, allowing Cl − ions to pass through.
X-ray crystal structures of related prokaryotic proton-gated ion channels have provided some insights into the structural rearrangement that can occur during receptor gating. 15 ELIC (Erwinia chrysanthem ligand-gated ion channel) represents an inactive receptor conformation and GLIC (Gloebacter violaceus ligand-gated ion channels) represents a desensitized receptor conformation. 16, 17 Despite a lack of mammalian crystal structures, there is strong evidence that structural changes occur within the orthosteric binding site upon activation of the receptor by GABA 18 and that the binding site is constricted in the open conformation. 19 Tyrosine at position 102 (Y102) is located on loop D of the ρ 1 subunit within the GABA binding site. This residue has been proposed to be associated with agonist binding and channel gating. 20 Recently, this residue was demonstrated not to form a cation−π interaction with GABA 21 and in an alternative homology model of the ρ 1 GABA binding site implicates that this residue does not directly bind GABA. 22 Mutation of Y102 to serine (ρ 1Y102S ) in the ρ 1 subunit shifts the equilibrium of the receptor toward the open conformation, producing a constitutively active form of the receptor. 20 The competitive antagonist 3-aminopropyl-methyl-phosphinic acid (3-APMPA) inhibits the spontaneous current of ρ 1Y102S receptors in a concentration-dependent manner, 20 demonstrating that 3-APMPA acts as an inverse agonist, inducing a conformational change which shifts the equilibrium of the receptor toward the closed conformation.
In this study, the role of Y102 in antagonist activity was assessed. Y102 was mutated to serine (ρ 1Y102S ), cysteine (ρ 1Y102C ), and alanine (ρ 1Y102A ), and the resulting mutant receptors represent channels with a proportion in the open conformational state (ρ 1Y102S ) and almost entirely in the closed conformational state (ρ 1Y102C , ρ 1Y102A ) of the channel. Twelve known antagonists (1−7 and 9−13) and two novel antagonists (8 and 14) were evaluated on ρ 1 wild-type and mutant receptors to investigate if antagonist activity was altered with receptor conformation.
■ RESULTS AND DISCUSSION
The mechanism by which an agonist binds and subsequently opens the channel of Cys-loop receptors is complex and involves many structural changes throughout the receptor, including changes within the orthosteric binding site. Ligands, for example, 3-APMPA (2), have different affinities for the open or closed conformational states of the receptor, as the conformation of the binding site differs between the two conformational states. 20 Constitutively active receptors, such as the ρ 1Y102S receptor, provide an opportunity to assess the activity of antagonists on receptors in equilibrium between the open or closed conformational states of the receptor. ρ 1Y102S Receptors Are Constitutively Active. Consistent with previous studies, 20 the EC 50 values for GABA increased by 21-, 233-and 196-fold when ρ 1 Y102 was mutated to cysteine, serine, and alanine, respectively ( Figure 1 , Table 1 ). This change in GABA sensitivity suggests that mutation of Y102 on the ρ 1 subunit results in a change in GABA affinity or altered receptor gating. Of the three mutant receptors evaluated, ρ 1Y102S receptors were constitutively active. When clamped at −60 mV, the holding current for cells expressing ρ 1Y102S (−200.3 ± 20.1 nA, n = 11) was greater than that in cells expressing ρ 1 wild-type (−15.2 ± 4.0 nA, n = 11), ρ 1Y102A (−0.2 ± 1.7 nA, n = 11), and ρ 1Y102C (−5.6 ± 4.1 nA, n = 11) mutant receptors. This suggests that while ρ 1Y102S receptors exist in equilibrium between the open and closed conformational states, while ρ 1 wild-type, ρ 1Y102A , and ρ 1Y102C receptors predominantly prefer the closed conformational state.
(±)-4-ACPAM (8) and SR-95813 (14) Are Potent Antagonists at ρ 1 Receptors. In this study, a total of 12 known and 2 novel agents were evaluated at ρ 1 receptors. TPMPA (1), 3-APMPA (2), SGS-742/CGP-36742 (3), (±)-cis-3-ACPBPA (4), (±)-3-trans-ACPBPA (5), S-4-ACPB-PA (6), (+)-S-4-ACPCA (7), THIP (9), DAVA (10), 4-GBA (11), ZAPA (12) , and SR-93351/Gabazine (13) have been shown previously to act as competitive antagonists at ρ 1 wildtype receptors, indicating that they bind to the GABA binding site. The activities of two novel ligands, (±)-4-ACPAM (8) and SR-95813 (14) , were characterized at ρ 1 wild-type receptors recombinantly expressed in Xenopus oocytes. These novel compounds are interesting in that they do not possess an acid moiety (carboxylic or phosphinic acid), a feature common to all ligands that bind to the GABA binding site. Instead of the usual acid moiety, (±)-4-ACPAM (8) has an amide group, while SR-95813 (14) has a nitrile group. To our surprise, these compounds were found to be potent ρ 1 receptor competitive antagonists. Figure 2A demonstrates that (±)-4-ACPAM (8) inhibits the EC 50 of GABA (1 μM) in a concentrationdependent manner (Figure 2A , IC 50 = 9.6 ± 0.9 μM, n = 4). Schild plot analysis demonstrates that in the presence of increasing concentrations of (±)-4-ACPAM (8) (30, 100, and 300 μM; n = 3−4 oocytes per antagonist concentration), the concentration response curve for GABA is shifted to the right in a parallel manner ( Figure 2B , K B = 30.3 ± 3.1 μM, slope did not differ from 1, see Figure 2 Supporting Information), indicating that (±)-4-ACPAM (8) is a competitive antagonist at ρ 1 wild-type receptors.
Similarly, SR-95813 (14) inhibits the response produced by GABA (1 μM) in a concentration-dependent manner ( Figure  2C , IC 50 = 8.0 ± 0.8 μM, n = 4). Schild plot analysis shows that in the presence of increasing concentrations of SR-95813 (14) (30, 100 and 300 μM; n = 3−4 oocytes per antagonist Figure 1 . GABA concentration response curves for human ρ 1 wildtype (WT) receptors and ρ 1Y102C , ρ 1Y102S and ρ 1Y102A receptors expressed in Xenopus oocytes. Each data point represents the mean ± SEM (n = 3−4). All data are normalized with I max, which refers to their maximum current. EC 50 values are listed in Table 1 . concentration), the GABA concentration response curve is shifted to the right in a parallel manner ( Figure 2D , K B = 12.4 ± 0.4 μM, slope did not differ from 1, see Figure 2 in the Supporting Information), indicating that SR-95813 (14) blocks ρ 1 wild-type receptors in a competitive manner. Mutagenesis studies of the ρ 1 receptor identified arginine 104 (R104) as important for GABA binding, and this residue is thought to interact via a salt bridge with the carboxylate group of GABA. 23 Homology models of the ρ 1 receptor support this observation. 22 As (±)-4-ACPAM (8) and SR-95813 (14) do not possess a carboxylate group, it would be interesting to evaluate R104 in the binding of these ligands.
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Assessing the Activity of Antagonists at a Proportion of Receptors in the Open Conformational State. The activities of 14 GABA antagonists (1−14) were evaluated using the constitutively active ρ 1Y102S receptors. Antagonists were tested at 100 and 300 μM in the absence of GABA. The percentage inhibition of the spontaneous current was measured and normalized to the initial resting current for each cell. All antagonists tested inhibited the spontaneous current of ρ 1Y102S receptors to a various extent when evaluated at 300 μM, with the exception of (±)-4-ACPAM (8) . (±)-4-ACPAM (8), at either 100 or 300 μM, failed to inhibit the spontaneous current at these receptors ( Figure 3B ).
Of the compounds tested, SGS-742 (3), S-4-ACPCA (7), (±)-4-ACPAM (8) and DAVA (10) were the weakest at inhibiting (0−9%) the constitutive current produced by ρ 1Y102S receptors. The remaining antagonists inhibited the current by 10−87% ( Table 2 ). 3-APMPA (2) was the most effective inhibitor of the constitutive current, while TPMPA (1), (±)-cis-3-ACPBPA (4), 4-GBA (11), SR-95331 (13), and SR-95813 (14) displayed moderate inhibition of the constitutive current.
To explore the relative activity of antagonists on the open conformational state of the ρ 1 receptor, we focused on five structurally different GABA antagonists, TPMPA (1), (±)-cis-3-ACPBPA (4), (±)-4-ACPAM (8), 4-GBA (11), SR-95531 (13) , and SR-95813 (14) ( Table 2 ). Application of the competitive antagonist, TPMPA (1), to ρ 1Y102S receptors inhibited the spontaneous current in a concentration-dependent manner ( Figure 3A ). This indicates that TPMPA shifts the equilibrium of ρ 1Y102S receptors from the open to the closed conformational state, thus acting as an inverse agonist (Table  2 ). However, TPMPA is weak exhibiting a 600-fold decrease in potency. Figure 3C shows the concentration response curves for TPMPA (1), (±)-cis-3-ACPBPA (4), (±)-4-ACPAM (8), 4-GBA (11) SR-95531 (13) , and SR-95813 (14) inhibiting the spontaneous current of ρ 1Y102S receptors. The affinities of the compounds against the spontaneous current were lower compared to the ρ 1 wild-type (Tables 2 and 3 ). The order of potency of the compounds at ρ 1Y102S receptors was SR-95813 (14) > SR-95531 (13) > (±)-cis-3-ACPBPA (4) > 4-GBA (11) > TPMPA (1) ( Table 3 ). (±)-4-ACPAM (8) had a very small effect on the constitutive activity of ρ 1Y102S receptors even at the 1 mM concentration ( Figure 3C ) and failed to significantly inhibit GABA (EC 50 ; 180 μM) at this mutant receptor ( Figure  3D ).
Interestingly, both SR-95531 (13) and SR-95813 (14) could not completely block the spontaneous current of ρ 1Y102S receptors ( Figure 3C ), indicating they may act as partial inverse agonists at the mutant receptor. Furthermore, in the presence of GABA, both SR-95531 (13) and SR-95813 (14) inhibited GABA with IC 50 values approximately 2-fold weaker than the EC 50 value that inhibits the constitutive activity (Table  3 and 4, Figure 4 ), suggesting the binding affinity of these compounds are similar in the presence or absence of GABA at ρ 1Y102S receptors.
Assessing the Activity of Antagonists at Receptors in the Closed Conformation State. The activities of the five antagonists were examined at ρ 1Y102C and ρ 1Y102A receptors (Table 4, Figure 5 ). In contrast to ρ 1Y102S receptors, ρ 1Y102C and ρ 1Y102A receptors were not constitutively active, thus existing predominantly in the closed conformational state. Interestingly, (±)-4-ACPAM (8) at a concentration of 300 μM regained some of its antagonist activity for the ρ 1Y102C and ρ 1Y102A mutant receptors (Table 4 ). At ρ 1Y102C receptors, (±)-4-ACPAM (8) displayed a 25-fold increase in IC 50 compared to ρ 1 wild-type (At ρ 1 wild-type; IC 50 = 9.6 ± 0.9 μM: at ρ 1Y102C ; IC 50 = 241.8 ± 17.2 μM). As (±)-4-ACPAM (8) did not inhibit the constitutive activity of ρ 1Y102S mutant receptors, nor did it inhibit GABA ( Figure 3B and D) or the inverse agonist effects of SR-95531 (13) (see Figure 3 in the Supporting Information) at this receptor, we can infer that either tyrosine is crucial for the binding of (±)-4-ACPAM (8) or that (±)-4-ACPAM (8) acts at receptors existing predominantly in the closed over the open conformational state.
At ρ 1Y102C receptors, the IC 50 values for TPMPA (1), (±)-cis-3-ACPBPA (4) and 4-GBA (11) were also increased by 200-, 22-and 25-fold, respectively, compared to ρ 1 wild-type receptors ( Table 4 ). As the cysteine and alanine mutations did not affect potency of the antagonists to the same extent as the serine mutation, indicating that these compounds have the ability to preferentially bind to the closed conformational state of the receptor. A similar phenomenon is observed with tetracaine at nicotinic acetylcholine (nACh) receptors. 24 Tetracaine has a 100-fold higher affinity for the close conformation compared the desensitized conformation of the Torpedo nACh receptor, implicating tetracaine is a closed conformation channel blocker.
In contrast to what was observed at ρ 1Y102S receptors, the inhibitory activity of SR-95531 (13) and its analogue SR-95813 (14) was significantly reduced at both ρ 1Y102C and ρ 1Y102A receptors. SR-95531 (13) (300 μM) inhibited only 7.5% of the current elicited by GABA EC 50 (20 μM) at ρ 1Y102C receptors and was inactive at ρ 1Y102A receptors ( Figure 6 , Table 4 ). Furthermore, SR-95813 (14) (300 μM) did not inhibit the current elicited by GABA EC 50 (20 μM) at both ρ 1Y102C and ρ 1Y102A receptors ( Figure 6 , Table 4 ). Thus, the order of potency of the compounds tested at ρ 1Y102C receptors was (±)-cis-3-ACPBPA (4) > (±)-4-ACPAM (8) > 4-GBA (11) ≅ TPMPA (1) ≫ SR-95531 (13) ≅ SR-95318 (14) . As SR-95531 (13) and its analogue SR-95813 (14) are more potent on ρ 1Y102S than ρ 1Y102C receptors, may indicate that the compounds are more likely to bind to the open over the closed conformational state of the receptor. While we cannot rule out the possibility of direct interaction between the introduced residues and the antagonists tested, there is no clear structure activity relationship to suggest that either possibility may be the case.
Previous studies have shown that mutating Y102 of the ρ 1 subunit to phenylalanine alters the effect of SR-95531 (13) 25 and that the mutation of the homologous residue in the GABA A receptor α 1 -subunit (phenylalanine at position 64) to cysteine dramatically changes the affinity of SR-95531. 26 The data presented in this study using SR-95531 (13), SR-95813 (14), (±)-cis-3-ACPBPA (4), (±)-4-ACPAM (8), 4-GBA (11), and TPMPA (1) provides further support that Y102 plays a key role Figure 1 in Supporting Information. k See Figure 2 in Supporting Information. NA stands for not active at the concentration. in binding/gating. However, the activity of SR-95531 (13) and its analogue SR-95813 (14) is not dramatically changed when ρ 1Y102 is mutated to serine. This indicates that, at least with the gabazine analogues, π−π interactions are not the main interactions affecting the activity of these compounds at ρ 1 receptors, despite an improved affinity of SR-95531 (13) when Y102 is mutated to phenylalanine. 25 This supports the homology model which infers that Y102 does not directly interact with GABA 22 and is most likely a residue involved in channel gating. In support of this conclusion, the partial agonist imidazole-4-acetic acid (I4AA) activated the ρ 1Y102C mutant receptor with high efficacy and lower potency compared to ρ 1 wild-type, 20 consistent with Y102 being a residue involved in gating.
■ CONCLUSION
In conclusion, the affinity of ρ 1 receptor antagonists is dependent on the receptor conformation as a result of the introduced mutations. In this study we investigated the potencies of a range of antagonists at ρ 1 wild-type, ρ 1Y102S , ρ 1Y102C , and ρ 1Y102A mutant receptors. It was found that the acid moiety that is a common feature of most ρ 1 antagonists was not found to be critical for antagonist activity, as demonstrated with (±)-4-ACPAM (8) and SR-95813 (14) . We also confirmed that Y102 plays important role in the potency of (±)-4-ACPAM (8), SR-95531 (13) and SR-95813 (14) . In addition, (±)-4-ACPAM (8) is more potent for closed conformational state of the ρ 1 receptor, while SR-95531 (13) and its analogue SR-95318 ( prop-2-enoic acid], 32 SR-95531 (gabazine), 33 and SR-95813 33 were synthesized according to our previously published methods. 27−33 GABA (γ-aminobutyric acid), THIP (4,5,6,7-tetrahydroisoxazolo- [5,4-c] pyridin-3-ol), and DAVA (5-aminovaleric acid) were purchased from Sigma-Aldrich Chemical Co. (St Louis, MO). 3-APMPA (3aminopropyl(methyl)phosphinic acid) was purchased from Tocris Bioscience (Bristol, U.K.). CGP-36742 or SGS-742 (3-aminopropyl-nbutylphosphinic acid) was a gift from Dr. Wolfgang Froestl (formerly Novartis, Switzerland).
Synthetic Procedure and Characterization Data for (±)-4-ACPAM (8) ((±)-4-Aminocyclopent-1-enecarboxamide). Methyl 4-tert-butoxycarbonylaminocyclopent-1-enecarboxylate 34 (2.90 g, 12 mmol) was added to an aqueous solution of 0.5 M sodium hydroxide (80 mL) and tetrahydrofuran (40 mL) and allowed to stir overnight at room temperature. Excess tetrahydrofuran was removed from this solution under reduced pressure followed by extraction with dichloromethane (60 mL). The remaining aqueous fraction was acidified to pH 3 with 10% aqueous citric acid in the presence of dichloromethane (180 mL). The combined organic phases were dried over magnesium sulfate and evaporated to give 4-tert-butoxycarbonylaminocyclopent-1-enecarboxylic acid (2.59 g, 95% yield). R f = 0. Triethylamine (304 mg, 3 mmol) was added to a solution of 4-tertbutoxycarbonylaminocyclopent-1-enecarboxylic acid (7, 341 mg, 1.5 mmol) in tetrahydrofuran (30 mL) at 0°C. iso-Butylchoroformate (338 mg, 2.5 mmol) was added dropwise, and the solution left to stir for 15 min. Gaseous ammonia was bubbled through the solution for 20 min and the reaction left to stir at 0°C for a further 2 h. The reaction was concentrated in vacuo, diluted with ethyl acetate (30 mL), and washed with aqueous sodium hydroxide (1 M, 10 mL), saturated citric acid (10 mL), and brine (10 mL). The organic fraction was dried over sodium sulfate and solvent was removed under reduced pressure. The product was isolated using flash chromatography, eluting with ethyl acetate/dichloromethane (10:1) to give tert-butyl 3-carbamoylcyclopent-3-enylcarbamate (315 mg, 92% yield). R f = 0.47 (ethyl acetate Site-Directed Mutagenesis. Serine, cysteine, and alanine mutations were generated at the position 102 of ρ 1 subunit by using sense and antisense oligonucleotide primers ( Table 1 in the Supporting Information) and the QuickChange II Site-directed Mutagenesis kit protocol (Stratagene, La Jolla, CA). All mutations were verified by DNA sequencing to confirm fidelity (Australian Genome Research Facility, Australia). The plasmids containing wildtype and mutations inserts were linearized with Xba-I, and T7 mMESSAGE mMACHINE kit (Ambion, Austin, TX) was used for mRNA synthesis.
Expression of Wild-Type and Mutant ρ 1 Receptors in Xenopus Oocytes. Oocytes from Xenopus laevis (South Africa clawed frogs) were harvested as described previously 35 in accordance with the National Health and Medical Research Council of Australia's ethical guidelines and approved by the University of Sydney Animal Ethics Committee. Stage V−VI oocytes were injected with 10−15 ng cRNA and then stored at 18°C in ND 96 solution (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl 2 , 1 mM MgCl 2 , 5 mM HEPES, pH 7.5) supplemented with 2.5 mM sodium pyruvate, 0.5 mM theophylline, 50 μg mL −1 gentamycin, and 2.5 mg mL −1 tetracycline.
Electrophysiological Recordings. Two to eight days after injections, the activity was measured by two-electrode voltage clamp recording using a Geneclamp 500 amplifier (Axon Instruments, Foster City, CA), a MacLab 2e recorder (AD Instruments, Sydney, NSW, Australia), and Chart version 5.5.6 program as previously described. 8 Briefly, oocyte expression receptors were clamped at −60 mV with continuous flow of ND96 buffer. Antagonists were screened for inverse agonist activity by applying increasing concentrations (100 and 300 μM) on ρ 1 receptors. SR-95531 (13) and SR-95813 (14) were dissolved in DMSO, and the compounds concentrations were made with the total concentration of 0.8% DMSO. SR-95531 (13) and SR-95813 (14) were not tested higher than 3 mM concentration due to the solubility issues at high concentrations. Antagonist effects were tested in the presence of GABA EC 50 concentration (20 μM for ρ 1Y102C and 200 μM for ρ 1Y102A receptors) on ρ 1Y102C and ρ 1Y102A receptors, and the effects were evaluated for their inhibitory concentration−response actions using ρ 1Y102C receptors. For selected antagonists, concentration−inhibition curves were constructed with a minimum of three cells.
Data Analysis. Current responses were normalized to the maximum GABA-activated current recorded in the same cell and expressed as a percentage of this maximum and fitted by least-squares to Hill equation (eq 1). GABA concentration response curves were generated using GraphPad PRISM 5.02 (GraphPad software San Diego, CA).
